MENU

Eric M. Horwitz, MD

Eric Horwitz, MD

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Treatment Focus

  • Intensity Modulated Radiation Therapy (IMRT)
  • Stereotactic body Radiation Therapy (SbRT)
  • HDR temporary prostate brachytherapy
  • LDR permanent prostate brachytherapy

Key Awards

  • Inaugural Fellow, American Brachytherapy Society (ABS), 2017
  • Philadelphia magazine Top Docs, 2002, 2005-2017
  • America’s Top Doctors® 2015-2017
  • Newsweek Top Cancer Doctors, 2015
  • Best Doctors in America® 2013-2014

Treatment Philosophy

In addition to my focus on treating and caring for patients with prostate and bladder cancer, it is my responsibility as Chairman of the Department of Radiation Oncology at Fox Chase; an NCI designated National Comprehensive Cancer Center to promote the mission of the Center to prevail over cancer. Our department's expertise has always focused on developing and integrating sophisticated technology into successful treatment for our cancer patients and I remain committed to continuing and expanding this legacy. However, the successful treatment of a patient is not just based on the technology that is available. Being diagnosed with cancer and receiving treatment is one of the most difficult things that many people will ever face, and it is crucial that we as caregivers do not forget this. Caring for patients as one important part of a multidisciplinary team allows us in the Department of Radiation Oncology to provide the best possible care for our patients.

Chair, Radiation Oncology
 

Since joining the staff in 1997, Dr. Horwitz's contributions include spearheading the clinical program as it grew exponentially in size and patient volumes. He developed advanced treatment programs using intensity-modulated radiation therapy (IMRT), image-guided radiation therapy and brachytherapy, including high-dose-rate (HDR) brachytherapy for prostate cancer.

As a result, Fox Chase was the first in the northeastern United States to offer HDR implants to men with prostate cancer.

In addition, Dr. Horwitz integrated the use of an MRI treatment simulator into prostate cancer treatment planning for both permanent, low-dose prostate implants and external radiation therapy. Fox Chase was the first in the world to use MRI in radiation treatment planning... Expand

Education, Training & Credentials

Educational Background

  • Resident, Radiation Oncology, William Beaumont Hospital, Royal Oak, MI
  • MD, Albany Medical College, Albany, NY, 1992
  • BA, History, Chemistry minor, University of Pennsylvania, Philadelphia, PA, 1988

Certifications

  • American Board of Radiology, Radiation Oncology

Memberships

  • National Comprehensive Cancer Network (NCCN)
    • Prostate Cancer Panel
  • American Society of Radiation Oncology (ASTRO)
  • American Brachytherapy Society (ABS)
  • American Board of Radiology (ABR)
  • American Medical Association (AMA)

Honors & Awards

  • Inaugural Fellow, American Brachytherapy Society (ABS), 2017
  • Philadelphia Magazine Top Docs, 2002, 2005-2017
  • America’s Top Doctors®, 2015-2017
  • Newsweek Top Cancer Doctors, 2015
  • Best Doctors in America®, 2013-2014
  • Volunteer Service Award, American Board of Radiology, 2014
  • Distinguished Service Award, American Brachytherapy Society, 2010
Patient Stories

Daniel Haubrich

Prostate Cancer

Daniel Haubrich

Prostate Cancer

After Daniel Haubrich was diagnosed with prostate cancer in 2005, his urologist did not think he was a good candidate for surgery, and he offered Daniel little hope that he would make a full recovery. Daniel knew he needed a second opinion and scheduled an appointment at Fox Chase Cancer Center to see a more experienced surgeon. This time, he was recommended for surgery, and after both surgery and radiation in early 2006, he is now cancer free. "I am grateful to both Dr. Chen and Dr. Horwitz for their positive attitudes, their commitment to care, and for treating me with respect," he said. "My experience at Fox Chase was always positive."

Kevin Logan

Head & Neck Cancer

Kevin Logan

Head & Neck Cancer

In 2010, Kevin Logan noticed a lump on his neck which turned out to be squamous cell carcinoma on the base of his tongue. Upon the recommendation to seek treatment at Fox Chase Cancer, that's where Kevin and his wife, Devra, went even though it was a three-hour drive from their home in Maryland. Kevin underwent a successful treatment of surgery, chemotherapy, and radiation, and once he finished treatment, he returned to work full-time. "Many people who knew about my cancer often called to ask where I was treated, and I’m always telling them, 'Fox Chase is the place to go,' and I always will," he said.

Ed Horowitz

Prostate Cancer

Ed Horowitz

Prostate Cancer

When Ed Horowitz was diagnosed with prostate cancer in 2008, he had to make a decision whether to undergo radiation or surgery. After receiving one opinion from a surgeon at a large Philadelphia hospital, he decided to seek a second opinion from Dr. Eric Horwitz, chair of radiation oncology at Fox Chase Cancer Center. Ed liked Dr. Horowitz's warm demeanor and sense of humor and decided to be treated with IMRT (intensity modulated radiation therapy) combined with hormone injections, followed by radiation and hormone therapy. The treatment was successful. A few years later, his cancer returned, isolated to his shoulder this time. Ed started another course of chemotherapy in March 2016. "My cancer has not grown and has not spread since I completed chemotherapy," he said. "I always recommend Fox Chase to anyone considering treatment for prostate cancer. I consider myself fortunate to have gone there for treatment."

James Slade

Colorectal Cancer;  Prostate Cancer

James Slade

Colorectal Cancer;  Prostate Cancer

After a prostate cancer diagnosis, James Slade decided to seek a second opinion at Fox Chase Cancer Center, where his oncologist recommended the use of high dose conformal external beam radiation with daily image guidance as treatment. The procedure was successful, and Jim went back to his normal life. But four years later, in 2004, the cancer returned: except, this time, in his colon. Jim went back to Fox Chase for treatment, where he underwent minimally-invasive surgery followed by chemotherapy. In 2009, Jim reached the milestone of being cancer-free for five years. Jim returns to Fox Chase for check ups and says he feels good. "I know it's crazy to say, but I actually like going to Fox Chase," he said. "Fox Chase is wonderful. I never had any pain, even after the operation."

John Donahue

Prostate Cancer

John Donahue

Prostate Cancer

John Donahue was concerned about prostate cancer. From the time he had surgery for an enlarged prostate, John was always aware of his PSA (prostate-specific antigen) level (a protein produced by the cells of the prostate gland). Although his levels were within normal range, they were on an upward climb over a period of 3 to 4 years.

Pages

Research Profile

Research Interests

  • Determining outcomes in treatment for prostate cancer patients treated with external beam radiation and brachytherapy
  • Developing image guidance techniques for prostate cancer radiation
  • Developing new bladder preservation techniques to treat patients with muscle invasive bladder cancer
Publications

Selected Publications

Martin, J.M., Li, T., Johnson, M.E., Murphy, C.T., Howald, A.G., Smaldone, M.C., Kutikov, A., Chen, D.Y., Viterbo, R., Greenberg, R.E., Uzzo, R.G., Horwitz, E.M. Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center.  J Natl Compr Canc Netw  13:  525-30; 2015. PubMed

Horwitz, E.M. and Weinberg, D.S.  Medicare physician payment data: Is this transparency?  Ann. Int. Med.  161(4):  291-292; 2014. PubMed

Horwitz EM. ABS brachytherapy consensus guidelines. Brachytherapy. 11(1):  4-5, 2012. PubMed

Davis BJ, Horwitz EM, Lee WR, Crook, J. M.; Stock, R. G.; Merrick, G. S.; Butler, W. M.; Grimm, P. D.; Stone, N. N.; Potters, L.; Zietman, A. L.; Zelefsky, M. J.  American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.  Brachytherapy 11(1):6-19, 2012. PubMed

Crook, J.M.; O'Callaghan, C.J.; Duncan, G.; Dearnaley, D.P.; Higano, C.S.; Horwitz, E.M.; Frymire, E.; Malone, S.; Chin, J.; Nabid, A.; Warde, P.; Corbett, T.; Angyalfi, S.; Goldenberg, S.L.; Gospodarowicz, M.K.; Saad, F.; Logue, J.P.; Hall, E.; Schellhammer, P.F.; Ding, K.; Klotz, L.  Intermittent androgen suppression for rising PSA level after radiotherapy.  New England Journal of Medicine 367:  895-903; 2012. PubMed

Rosenthal, S.A.; Bittner, N.H.; Beyer, D.C.; Demanes, D.J.; Goldsmith, B.J.; Horwitz, E.M.; Ibbott, G.S.; Lee, W.R.; Nag, S.; Suh, W.W.; Potters, L.  American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.  International Journal of Radiation Oncology Biology Physics 79:  335-41; 2011.  PubMed

Horwitz, E.M.  Why External Beam Radiotherapy Is Treatment of Choice for Most Men With Early-stage Nonmetastatic Prostate Cancer.  Urology 73:  470-472; 2009. PubMed

Horwitz, E.M.; Bae, K.; Hanks, G.E.; Porter, A.; Grignon, D.; Brereton, H.; Venkatesan, V.; Lawton, C.A.; Rosenthal, S.A.; Sandler, H.M.; Shipley, W.U.  Ten-Year Follow-Up of RTOG 92-02:  A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer.  Journal of Clinical Oncology 26:  2497-2504; 2008. PubMed

Langer, C.J.; Harris, J.; Horwitz, E.M.; Nicolaou, N.; Kies, M.; Curran, W.J.; Wong, S.J.; Ang, K.K.  Phase II study of paclitaxel, cisplatin in combination with split course concomitant hyperfractionated re-irradiation in patients with recurrent squamous cell cancer of the head and neck cancer:  Preliminary results of RTOG 99-11.  Journal of Clinical Oncology 25:  4800-4805; 2007. PubMed

Horwitz, E.M.; Levy, L.B.; Thames, H.D.; Kuban, D.A.; Kupelian, P.A.; Martinez, A.A.; Michalski, J.M.; Pisansky T.M.; Sandler, H.M.; Shipley, W.U.; Zelefsky, M.J.; Hanks, G.E.; Zietman, A.L.  The Biochemical And Clinical Significance Of The Post-Treatment PSA Bounce For Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone: A Multi-Institutional Pooled Analysis.  Cancer 1071:  1496-1502; 2006. PubMed

Kuban, D.A.; Levy, L.B.; Potters, L.; Beyer, D.C.; Blasko, J.C.; Moran, B.J.; Ciezki, J.P.; Zietman, A.L.; Zelefsky, M.J.; Pisansky, T.M.; Elshaikh, M.; Horwitz, E.M.  Comparison of biochemical failure definitions for permanent prostate brachytherapy.  International Journal of Radiation Oncology Biology and Physics 65:  1487-1493; 2006. PubMed

Horwitz, E.M.; Thames, H.D.; Kuban, D.A.; Levy, L.B.; Kupelian, P.A.; Martinez, A.A.; Michalski, J.M.; Pisansky T.M.; Sandler, H.M.; Shipley, W.U.; Zelefsky, M.J.; Hanks, G.E.; Zietman, A.L.  Definitions Of Biochemical Failure That Best Predict Clinical Failure In Prostate Cancer Patients Treated With External Beam Radiation Alone - A Multi-Institutional Pooled Analysis.  Journal of Urology 173:797-802; 2005. PubMed

Horwitz, E.M.; Uzzo, R.G.; Hanlon, A.L.; Greenberg, R.E.; Hanks, G.E.; Pollack, A.  Modifying the ASTRO definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3D conformal radiation therapy alone.  Journal of Urology 169:  2153-2159; 2003. PubMed

Hanks, G.E.; Hanlon, A.L.; Epstein, B.; Horwitz, E.M.  Dose response in prostate cancer with 8-12 year follow-up.  International Journal of Radiation Oncology Biology and Physics 54:  427-435; 2002. PubMed

 

 

 

 

 

 

 

 

 

 

Additional Publications

My NCBI